Contact

Crossroot Home About Services Safety Comparison Evidence & Policy Retreat Risk Checklist Contact A careful comparison Ibogaine Vs Ayahuasca They are not interchangeable. Their origins, pharmacology, intended settings, legal context, and safety concerns differ in ways that matter before anyone treats either as a simple option. Evidence first risk aware A comparison should begin with differences in risk, evidence, culture, and law—not with a promise of a preferred path. Ibogaine is an indole alkaloid from Tabernanthe iboga root bark, studied as a potential treatment for opioid use disorder, alcohol use disorder, PTSD, and related conditions. Ayahuasca is a traditional Amazonian brew typically made from Banisteriopsis caapi plus a DMT-containing plant such as Psychotria viridis , and is used in ceremonial contexts while being studied for depression, trauma, and addiction-adjacent outcomes. Both are moving from fringe retreat use toward regulated research and policy debates, but neither is a routine, FDA-approved mainstream treatment in the United States. The difference between ibogaine and ayahuasca is not merely a matter of intensity or setting; it is a distinction in pharmacology and medical risk. Three foundations What separates the two A careful reading keeps the central distinctions visible rather than reducing either substance to a broad psychedelic category. I Origin & context Ibogaine is associated with West African botanical traditions and contemporary addiction-interruption research. Ayahuasca has a distinct Amazonian ceremonial history and should not be separated from that cultural context. II Duration & effects Typical ayahuasca ceremonies are often described as lasting 4–8 hours. Ibogaine experiences are commonly described as lasting 18–36 hours, creating a substantially different time and monitoring burden. III Primary safety concern QT prolongation and arrhythmia risk are repeatedly identified as ibogaine’s central acute medical hazard. Ayahu

Contact

A considered route for correspondence.